“The driving force for this was understanding whether we have made improvements as surgeons over time in how we're able to remove the prostate, but then also what types of functional outcomes patients have with regards to urinary function and sexual function,” says Udit Singhal, MD.
“There's going to be new techniques that we're not even aware of yet to try and break up the stones in a better fashion, but in a less invasive way for patients,” says Ben H. Chew, MD, MSc, FRCSC.
"Patients who have a female surgeon are about 25% less likely to die than if they had a male surgeon," says Christopher J.D. Wallis, MD, PhD.
“As we increase spending, we know there are good data out there that we haven't seen reflective improvement in outcomes or decreasing complications when we treat our patients,” says Randall A. Lee, MD.
"We're currently doing a multicenter, prospective study using the new Boston Scientific scope to measure intrarenal pressure for every ureteroscopy that we perform to get more data and to be able to identify these patients earlier, before they get septic," says Naeem Bhojani, MD, FRCSC.
“Another effort could be querying recent applicants or current applicants and seeing what information about diversity, equity, and inclusion would be important to them,” says Keiko Cooley, MD.
"It was really wonderful to work with a lot of our coauthors for the chapters because they really are thought leaders in the field," says Edward M. Schaeffer, MD, PhD.
The radionuclide-drug conjugate 225Ac-J591 combines J591, a monoclonal antibody that recognizes PSMA, with actinium-225, a potent alpha emitter.
"Just really try to have awareness; figure out, what do you really need right now? Once you realize what you need, have compassion, stop the judgment," says Diana Londoño, MD.
"What we found was that if during ureteroscopy your intrarenal pressure remains below 30 mm of mercury, there shouldn't be any infectious complications," says Naeem Bhojani, MD, FRCSC.
"I think that there could have been some expectation to see this lack of advertisement or engagement with DEI, particularly in urology given its current demographics," says Keiko Cooley, MD.
“Where I have found that it has been incredibly useful has been in those unfavorable intermediate-risk patients or those individuals who are kind of borderline at the risk spectrum,” says Rana R. McKay, MD.
“The purpose of the course is really to bring together like-minded surgeons and physicians who are interested in robotic reconstructive surgery to really come together to not only build a network, but also discuss complex situations, discuss tips and tricks, and also to review the most salient literature in this space,” says Ziho Lee, MD.
"Given that these lesions are common, even if surgeons aren't treating adrenal tumors, they're certainly going to find some on imaging," says Neal E. Rowe, MD, FRCSC.
“I was of course flattered when Dr. Walsh and Janet Worthington approached me to take the lead on editing and writing this fifth version of the book,” says Edward M. Schaeffer, MD, PhD.
"It's very important to build trust early on for a urologist and with a patient so that they're more likely to stay with a screening program," says Daniel E. Spratt, MD.
Joshi Alumkal, MD, highlights findings from the phase 3 ARASENS trial that led to the FDA approval of darolutamide for use in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.
“About 25% of men didn't even want to know that they had cancer,” says Daniel E. Spratt, MD.
"Sometimes, when you just look at people in the eye, you sort of can forget about everything else; you can just focus on that person in front of you," says Diana Londoño, MD.
“What's so great about the ArteraAI platform is the simplicity in which this test is performed,” says Rana R. McKay, MD.
“It’s exciting that now in 2023 we have 3 FDA-approved PARP inhibitors for the treatment of our prostate cancer patients,” says Joshi Alumkal, MD.
“When we are starting to do this in urology across the world, we need to make sure that we have patient representatives involved and they are there from the beginning to make sure that whatever we do in terms of an intervention is successful,” says Nikita R. Bhatt, MBBS, MCh, MMed, FRCS.
Joshi Alumkal, MD, discusses the phase 3 TALAPRO-2 trial, which supported the FDA approval of the combination of talazoparib and enzalutamide for patients with metastatic castration-resistant prostate cancer whose tumors harbor homologous recombination repair gene defects.
“So far, all the studies have shown quite positive results with this approach. It's something that we can use in urology [for a lot of different issues],” says Nikita R. Bhatt, MBBS, MCh, MMed, FRCS.
In the setting of refractory urothelial carcinoma, Jue Wang, MD, says it is essential to thoroughly understand a patient's molecular profile, comorbidities, and residual side effects from prior lines of therapy.
“The recommendations are based on the current evidence, but the evidence is overall relatively weak. So, I think there's a lot of room for improvement,” says Neal E. Rowe, MD, FRCSC.
"When a patient or an imaging study identifies an incidental adrenal mass, the first upfront radiographic test is a non-contrast CT scan," says Neal E. Rowe, MD, FRCSC.
"We as a center prioritized using cisplatin and carboplatin for patients who are receiving curative intent chemotherapy," says Tian Zhang, MD.
“At its core, [the book is] a love letter to my patients. It's all the things that I didn't have time to tell them in a 15-minute office visit,” says Martha Boone, MD.
